| 达沙替尼不同治疗方案治疗慢性髓细胞白血病疗效的Meta分析 |
| Alternative Title | Effectiveness of Different Regimes of Dasatinib for Chronic Myeloid Leukemia: A Meta-Analysis
|
| 郭敏 |
| Thesis Advisor | 席亚明
|
| 2013-05-21
|
| Degree Grantor | 兰州大学
|
| Place of Conferral | 兰州
|
| Degree Name | 硕士
|
| Keyword | 达沙替尼
慢性髓细胞白血病
Meta分析
系统评价
随机对照试验
|
| Abstract | 目的 系统评价达沙替尼140mg，1/日和70mg，2/日治疗慢性髓细胞白血病的疗效。方法 计算机检索Embase（1974-2011.11）、PubMed（1966-2011.11）、Cochrane library（2011年第11期）、CBM（1979-2011.11）、VIP（1989-2011.11）、CNKI（1994-2011.11）和WanFang Data（1997-2011.11）等数据库并手工检索相关领域的杂志，查找达沙替尼140mg，1/日和70mg，2/日治疗慢性髓细胞白血病（CML）的随机对照试验。对符合纳入标准的随机对照试验，由两位评价员按Cochrane系统评价的方法，独立进行资料提取、质量评价并交叉核对后，采用RevMan 5.1软件进行Meta分析。结果 共纳入4个研究，862例患者。Meta分析结果显示，两种方案长期治疗CML时，两者完全血液学缓解（CHR）[RR=0.97，95%CI(0.88,1.07)，P=0.58] 、完全细胞遗传学缓解（CCyR）[RR=0.94，95%CI(0.80,1.11)，P=0.47]及主要细胞遗传学缓解（MCyR）[RR=0.99，95%CI(0.86,1.13)，P=0.86] 差异均无统计学意义；短期治疗CML慢性期时，CHR、CCyR及MCyR差异也均无统计学意义；对长期治疗CML慢性期及进展期进行亚组分析，结果显示其CHR、CCyR及MCyR差异均无统计学意义。结论 达沙替尼140mg，1/日和70mg，2/日治疗CML的疗效相似。 |
| Other Abstract | Objective To systematically evaluate the effectiveness of dasatinib 140mg qd and 70mg bid for CML.
Methods The RCTs were retrieved from Embase (1974-2011.11), Pubmed (1966-2011.11), the Cochrane Library (Issue 11, 2011), CBM (1979-2011.11), VIP (1989-2011.11), CNKI (1994-2011.11), Wanfang Data (1997-2011.11) and references listed in all articles. RCTs meeting inclusive criteria were included the data were extracted, the quality was evaluated and cross-checked by two reviewers independently according to Cochrane Handbook for Systematic Reviews of Interventions and then meta-analyses were conducted using RevMan 5.1 software.
Results A total of four studies and 862 patients were included. Results of meta-analyses showed that when dasatinib was used in the long-term treatment of CML, no significant difference was found between 140mg qd and 70mg bid in the CHR (RR=0.97, 95%CI 0.88 to 1.07,P=0.58), CCyR (RR=0.94,95%CI 0.80 to 1.11,P=0.47) and MCyR (RR=0.99,95%CI 0.86 to 1.13,P=0.86). In the short-term treatment of CML, there were no significant differences in the CHR, CCyR and MCyR. The subgroup analyses on the long-term treatment of CML in both chronic phase and advanced phase showed that there were no significant differences in the CHR, MCyR and CCyR.
Conclusion In the effectiveness of dasatinib for CML, the dose of 140mg qd is similar to the dose of 70mg bid. |
| URL | 查看原文
|
| Language | 中文
|
| Document Type | 学位论文
|
| Identifier | https://ir.lzu.edu.cn/handle/262010/223707
|
| Collection | 学院待认领
|
| Affiliation | 临床医学院
|
Recommended Citation
GB/T 7714 |
郭敏. 达沙替尼不同治疗方案治疗慢性髓细胞白血病疗效的Meta分析[D]. 兰州. 兰州大学,2013.
|
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
